Bisphosphonate action on bone structure and strength: Preclinical and clinical evidence for ibandronate

Bone

Volumn 41, Issue 5 SUPPL. 1, 2007, Pages

  Müller, Ralph ^a   Recker, Robert R ^b  

^a ETH ZURICH   (Switzerland)

^b CREIGHTON UNIVERSITY   (United States)

Author keywords

Animal models; Bone strength; Bone structure; Histomorphometry; Ibandronate

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; IBANDRONIC ACID; PLACEBO; RISEDRONIC ACID;

ARTICLE; BONE STRENGTH; BONE STRUCTURE; BONE TURNOVER; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; HUMAN; NONHUMAN; POSTMENOPAUSE OSTEOPOROSIS;

EID: 35348844148     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2007.08.004     Document Type: Article

References (30)

1. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 19 (1998) 80-100
2. Russell R.G., and Rogers M.J. Bisphosphonates: from the laboratory to the clinic and back again. Bone 25 (1999) 97-106
3. Shinoda H., Adamek G., Felix R., Fleisch H., Schenk R., and Hagan P. Structure-activity relationships of various bisphosphonates. Calcif Tissue Int 35 (1983) 87-99
4. van Beek E., Hoekstra M., van de Ruit M., Lowik C., and Papapoulos S. Structural requirements for bisphosphonate actions in vitro. J Bone Miner Res 9 (1994) 1875-1882
5. Hodgson S.F., Watts N.B., Bilezikian J.P., Clarke B.L., Gray T.K., Harris DW., et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract 9 (2003) 544-564
6. Committee for Medicinal Products for Human Use (CHMP). Guideline on the evaluation of new medicinal products in the treatment of primary osteoporosis (2005), European Medicines Agency, London
7. United States Food and Drug Administration. Guidelines for preclinical and clinical evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis (1994)
8. World Health Organization. Guidelines for preclinical evaluation and clinical trials in osteoporosis (1998)
9. Turner C.H., and Burr D.B. Basic biomechanical measurements of bone: a tutorial. Bone 14 (1993) 595-608
10. Lalla S., Hothorn L.A., Haag N., Bader R., and Bauss F. Lifelong administration of high doses of ibandronate increases bone mass and maintains bone quality of lumbar vertebrae in rats. Osteoporos Int 8 (1998) 97-103
11. Guy J.A., Shea M., Peter C.P., Morrissey R., and Hayes WC. Continuous alendronate treatment throughout growth, maturation, and aging in the rat results in increases in bone mass and mechanical properties. Calcif Tissue Int 53 (1993) 283-288
12. Bauss F., Lalla S., Endele R., and Hothorn L.A. Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties, and bone concentration of ibandronate in ovariectomized aged rats. J Rheumatol 29 (2002) 2200-2208
13. Monier-Faugere M.C., Geng Z., Paschalis E.P., Qi Q., Arnala I., Bauss F., et al. Intermittent and continuous administration of the bisphosphonate ibandronate in ovariohysterectomized beagle dogs: effects on bone morphometry and mineral properties. J Bone Miner Res 14 (1999) 1768-1778
14. Toolan B.C., Shea M., Myers E.R., Borchers R.E., Seedor J.G., Quartuccio H., et al. Effects of 4-amino-1-hydroxybutylidene bisphosphonate on bone biomechanics in rats. J Bone Miner Res 7 (1992) 1399-1406
15. Balena R., Toolan B.C., Shea M., Markatos A., Myers E.R., Lee S.C., et al. The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest 92 (1993) 2577-2586
16. Smith S.Y., Recker R.R., Hannan M., Muller R., and Bauss F. Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys. Bone 32 (2003) 45-55
17. Müller R., Hannan M., Smith S., and Bauss F. Intermittent ibandronate preserves bone quality and bone strength in the lumbar spine after 16 months of treatment in the ovariectomized cynomolgus monkey. J Bone Miner Res 19 (2004) 1787-1796
18. Borah B., Dufresne T.E., Chmielewski P.A., Gross G.J., Prenger M.C., and Phipps R.J. Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by three-dimensional microcomputed tomography. J Bone Miner Res 17 (2002) 1139-1147
19. Muhlbauer R.C., Bauss F., Schenk R., Janner M., Bosies E., Strein K., et al. BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 6 (1991) 1003-1011
20. Chavassieux P.M., Arlot M., and Meunier P.J. Clinical use of bone biopsy. In: Marcus R., Feldman D., and Kelsey J. (Eds). Osteoporosis (2001), Academic Press, San Diego 501-509
21. Recker R.R., and Barger-Lux M.J. Bone biopsy and histomorphometry in clinical practice. In: Favus M. (Ed). Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism (2006), American Society for Bone and Mineral Research, Washington DC
22. Recker R.R. Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study. Osteoporos Int 15 (2004) 231-237
23. Recker R.R., Ste-Marie L.G., Czerwinski E., Rowell L., Bonvoisin B., and Masanauskaite D. Intermittent intravenous ibandronate injections have a similar bone safety profile to daily oral dosing. Calcif Tissue Int 78 Suppl. 1 (2006) (Abstract P455)
24. Chesnut C.H., Skag A., Christiansen C., Recker R., Stakkestad J.A., Hoiseth A., et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19 (2004) 1241-1249
25. Delmas P.D., Adami S., Strugala C., Stakkestad J., Reginster J.Y., Felsenberg D., et al. Intravenous ibandronate injections in postmenopausal osteoporosis: 1-year findings from the DIVA study. Arthritis Rheum 54 (2006) 1838-1846
26. Emkey R., Zaidi V., Lewiecki E.M., Burdeska A., Mairon N., Rowell L., et al. Two-year efficacy and tolerability of intermittent intravenous ibandronate injections in postmenopausal osteoporosis: the DIVA study. Arthritis Rheum 52 (2005) 4060 (Abstract L8)
27. Recker R.R., Lappe J., Davies K.M., and Heaney R. Bone remodeling increases substantially in the years after menopause and remains increased in older osteoporosis patients. J Bone Miner Res 19 (2004) 1628-1633
28. Chavassieux P.M., Arlot M.E., Roux J.P., Portero N., Daifotis A., Yates A.J., et al. Effects of alendronate on bone quality and remodeling in glucocorticoid-induced osteoporosis: a histomorphometric analysis of transiliac biopsies. J Bone Miner Res 15 (2000) 754-762
29. Eriksen E.F., Melsen F., Sod E., Barton I., and Chines A. Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone 31 (2002) 620-625
30. Recker R.R., Kimmel D.B., Parfitt A.M., Davies K.M., Keshawarz N., and Hinders S. Static and tetracycline-based bone histomorphometric data from 34 normal postmenopausal females. J Bone Miner Res 3 (1988) 133-144